Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
13 clinical trials · Condition
◉ Watch Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
| Record | Firm | Date |
|---|---|---|
| Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma (NCT05202782) | Northwestern University | 2022-03-21 |
| CD19-Specific T Cells Post AlloSCT (NCT03579888) | M.D. Anderson Cancer Center | 2020-06-26 |
| huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (NCT03103971) | Fred Hutchinson Cancer Center | 2017-11-03 |
Track Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified automatically
Every clearance here is in the API, with alerts when new ones post.